Acorda Therapeutics, Inc.: Nasdaq/NYSE listing notice — Acorda Therapeutics delisted from Nasdaq, now trades OTC Pink under ACORQ after Chapter 11

Acorda Therapeutics, Inc.

Common stock ceased trading on Nasdaq on April 12, 2024; now quoted on OTC Pink Open Market under ACORQ.
Delisting triggered by failure to comply with Nasdaq Listing Rules 5101, 5110(b), and 5450(b)(1)(A) due to Chapter 11 proceedings and stockholders' equity below $10M.
Nasdaq will file Form 25 to remove securities from registration under Section 12(b) of the Exchange Act; delisting effective 10 days after filing.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Acorda Therapeutics, Inc. received a nasdaq delisting notice notice regarding other.

Exchange: nasdaq
Notice: delisting notice

Exact text from the filing

April 15, 2024, Acorda Therapeutics, Inc. (the “Company”) issued a press release announcing that the Company’s common stock ceased trading on the Nasdaq Stock Market on April 12, 2024 and began trading on the Pink Open Market under the symbol “ACORQ.” A copy of the press release is being filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0000950170-24-044938

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.